The landscape of therapeutic interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor stimulants taking center stage. Initially, compounds like Reta, demonstrating impressive glucose https://dianeilrr777444.dsiblogger.com/71870727/glp-3-receptor-agonists-reta-trizepatide-and-beyond